Skip to content

US · OCUL · BIOTECHNOLOGY

Ocular Therapeutix, Inc. (OCUL) intrinsic value and stock valuation

$5.57as of 2026-11-21 · Mkt cap 1.86B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ocular Therapeutix, Inc. DCF and intrinsic value

InvestorsCraft values OCUL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OCUL’s statements →

Ocular Therapeutix, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bedford, MA 01730 ocutx.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$51.8M+24.4% 5y CAGRd
20122025
Net income
-$-265.94M
20122025
Free cash flow
-$-216.89M
20122025
Total equity
$654.3M+53.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$51.8M$63.7M$58.4M$51.5M$43.5M
Operating income-$-270.02M-$-171.78M-$-82.38M-$-78.65M-$-78.04M
Net income-$-265.94M-$-193.51M-$-80.74M-$-71.04M-$-6.55M
EPSd-$-1.42M-$-1.22M-$-943.22K-$-859.63K-$-79.72K
Operating cash flow-$-204.88M-$-134.68M-$-70.23M-$-59.6M-$-65.55M
Capital expenditure-$-12.01M-$-1.29M-$-6.09M-$-3.71M-$-1.19M
Free cash flow-$-216.89M-$-135.97M-$-76.32M-$-63.32M-$-66.74M
Total assets$808.1M$457.9M$252.1M$149.3M$204.9M
Total debt$79.8M$75.8M$83.4M$64.3M$59M
Net debt-$-657.28M-$-316.32M-$-112.42M-$-38.02M-$-105.18M
Total equity$654.3M$315.3M$91.1M$35.4M$88M
Cash and short-term investments$737.1M$392.1M$195.8M$102.3M$164.2M
Income statement
20252024202320222021
Revenue$51.8M$63.7M$58.4M$51.5M$43.5M
Cost of revenue$6.57M$5.63M$5.28M$4.54M$4.41M
Gross profit$45.3M$58.1M$53.2M$47M$39.1M
Research and development expenses$197.1M$127.6M$61.1M$53.5M$50.1M
Selling, general and administrative expenses$118.3M$102.2M$74.5M$72.2M$67.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$315.4M$229.9M$135.5M$125.6M$117.2M
Cost and expenses$322M$235.5M$140.8M$130.2M$121.6M
Interest income$18.4M$20.3M$3.98M$800K$30K
Interest expense$11.8M$13.6M$11.3M$7.02M$6.67M
Depreciation and amortization$4.32M$3.79M$2.98M$2.11M$2.42M
Ebitda-$-249.78M-$-176.14M-$-66.42M-$-61.91M$2.54M
Operating income-$-270.02M-$-171.78M-$-82.38M-$-78.65M-$-78.04M
Total other income/expenses, net$4.08M-$-21.73M$1.65M$7.62M$71.5M
Income before tax-$-265.94M-$-193.51M-$-80.74M-$-71.04M-$-6.55M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-265.94M-$-193.51M-$-80.74M-$-71.04M-$-6.55M
Weighted average shares outstanding$187.2M$158.3M$79.8M$76.9M$76.4M
Weighted average diluted shares outstanding$187.2M$158.3M$85.6M$82.6M$82.2M
Balance sheet
20252024202320222021
Cash and short-term investments$737.1M$392.1M$195.8M$102.3M$164.2M
Net receivables$30.7M$32.4M$26.2M$21.3M$21.1M
Inventory$3.56M$3.04M$2.31M$1.97M$1.25M
Total current assets$782.1M$441M$232.2M$129.6M$191.3M
Property, plant and equipment, net$24.3M$15.3M$18.2M$17.9M$11.8M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.61M$0.00$0.00$0.00$0.00
Total non-current assets$25.9M$17M$19.8M$19.7M$13.6M
Total assets$808.1M$457.9M$252.1M$149.3M$204.9M
Accounts payable$4.15M$4.18M$4.39M$5.12M$4.59M
Short-term debt$2.82M$1.93M$1.59M$1.6M$1.62M
Deferred revenue$0.00$130K$260K$580K$0.00
Total current liabilities$50.8M$41.4M$34.9M$31.4M$26.3M
Long-term debt$77M$73.9M$81.8M$62.7M$57.4M
Deferred revenue, non-current$14M$14M$14.1M$13.4M$13M
Total non-current liabilities$102.9M$101.2M$126M$82.5M$90.6M
Capital lease obligations$2.81M$7.28M$8.46M$10.3M$7.55M
Total liabilities$153.8M$142.6M$160.9M$113.9M$116.9M
Common stock$20K$20K$10K$10K$10K
Retained earnings-$-1.16B-$-891.08M-$-697.58M-$-616.84M-$-545.8M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$654.3M$315.3M$91.1M$35.4M$88M
Total investments$1.61M$0.00$0.00$0.00$0.00
Total debt$79.8M$75.8M$83.4M$64.3M$59M
Net debt-$-657.28M-$-316.32M-$-112.42M-$-38.02M-$-105.18M
Cash flow statement
20252024202320222021
Net income-$-265.94M-$-193.51M-$-80.74M-$-71.04M-$-6.55M
Depreciation and amortization$4.32M$3.79M$2.98M$2.11M$2.42M
Stock-based compensation$43.2M$33.1M$17.8M$17M$15M
Change in working capital$7.71M-$-10.23M-$-7.41M$1.35M-$-2.9M
Accounts receivable$1.74M-$-6.21M-$-4.85M-$-190K-$-8.88M
Inventory-$-520K-$-730K-$-330K-$-720K-$-50K
Accounts payable-$-890K-$-320K$580K-$-620K$1.8M
Net cash provided by operating activities-$-204.88M-$-134.68M-$-70.23M-$-59.6M-$-65.55M
Investments in property, plant and equipment-$-12.01M-$-1.29M-$-6.09M-$-3.71M-$-1.19M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-11.88M-$-1.29M-$-6.09M-$-3.71M-$-1.19M
Common stock issued$561.7M$316.4M$118.1M$940K$980K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$561.7M$332.1M$169.8M$1.45M$2.85M
Net change in cash$345M$196.2M$93.5M-$-61.86M-$-63.89M
Cash at end of period$738.7M$393.7M$197.6M$104.1M$165.9M
Operating cash flow-$-204.88M-$-134.68M-$-70.23M-$-59.6M-$-65.55M
Capital expenditure-$-12.01M-$-1.29M-$-6.09M-$-3.71M-$-1.19M
Free cash flow-$-216.89M-$-135.97M-$-76.32M-$-63.32M-$-66.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ocular Therapeutix, Inc.

        Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

        CEO
        Pravin U. Dugel
        Employees
        325
        Beta
        0.88

        Explore

        Frequently asked questions

        What is the intrinsic value of Ocular Therapeutix, Inc. (OCUL)?

        Ocular Therapeutix, Inc. (OCUL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OCUL undervalued?

        OCUL trades at a price of $5.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.